Globe News Wire

31 May 2026, 22:59 UTC · 2h ago

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Source · https://www.globenewswire.com/news-release/2026/05/31/3303959/0/en/goss-investors-have-opportunity-to-lead-gossamer-bio-inc-securities-fraud-lawsuit-with-the-schall-law-firm.html

Read source

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Search tags

Story key points

2 claims · impact-rated

What matters in this story

1
Gossamer Bio, Inc. is facing a securities fraud class action lawsuit alleging false and misleading statements regarding its Phase 3 PROSERA study. — Allegations of clinical trial design failures and concealed adverse facts typically create significant sentiment drag and legal liability risks for biotech firms.
-0.60
2
The lawsuit specifically alleges that Gossamer Bio concealed adverse facts regarding controls for placebo response at certain testing sites. — Questioning the integrity of placebo controls in a Phase 3 study casts doubt on the efficacy data of the drug candidate, potentially impacting future FDA approval prospects.
-0.40

Ticker attribution

Model heads

Sentiment in this article

GOSS-1.00
The company is facing a securities fraud class action lawsuit alleging false and misleading statements regarding a Phase 3 study.

6 related stories

Newsfile Corp
1d ago
GOSS DEADLINE MONDAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action - GOSS
- class action
- clinical trials
- lawsuit
Read

News Impact Screener — Catch market-moving news before the crowd

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

What matters in this story

Sentiment in this article

GOSS DEADLINE MONDAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action - GOSS

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

What matters in this story

Sentiment in this article

GOSS DEADLINE MONDAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action - GOSS

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages POET Technologies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – POET

SES AI DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages SES AI Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SES

STLA DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Stellantis N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action - STLA

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

What matters in this story

Sentiment in this article

Next reads from the same story arc

GOSS DEADLINE MONDAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action - GOSS

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

What matters in this story

Sentiment in this article

Next reads from the same story arc

GOSS DEADLINE MONDAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action - GOSS

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages POET Technologies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – POET

SES AI DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages SES AI Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SES

STLA DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Stellantis N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action - STLA